PURPOSE: We determined the risk of disease specific mortality in patients with primary, low risk, noninvasive (G1pTa) bladder cancer and compared it to disease specific mortality in age and gender matched general populations. MATERIALS AND METHODS: We identified all patients with primary low risk cancer at our institution. We excluded those with adverse pathological features and then matched histopathology, pharmacy, hospital episode and Cancer Registry records. We reviewed case notes on patients with subsequent muscle invasion (progression) or disease specific mortality. Patients underwent post-resection surveillance and treatment using standard regimens. National and regional disease specific mortality rates were calculated from appropriate data. RESULTS: A total of 699 patients met study inclusion criteria. Median followup was 61 months (IQR 24-105). Of the patients 17 (2.4%) died of bladder cancer, including 13 of 14 with progression to muscle invasion and 4 of 19 with grade progression to high grade, nonmuscle invasive disease. On Cox regression analyses low grade dysplasia in the initial resection specimen and tumor weight were associated with disease specific mortality (p <0.003). Disease specific mortality in these patients was 5 times the background rate in matched populations. Limitations of this study include its retrospective nature and the low frequency of adverse events. CONCLUSIONS: Patients with low risk bladder cancer rarely progress to muscle invasion but they are at higher risk for disease specific mortality than the general population. Current surveillance regimens appear ineffective for detecting progression in time to alter prognosis.
PURPOSE: We determined the risk of disease specific mortality in patients with primary, low risk, noninvasive (G1pTa) bladder cancer and compared it to disease specific mortality in age and gender matched general populations. MATERIALS AND METHODS: We identified all patients with primary low risk cancer at our institution. We excluded those with adverse pathological features and then matched histopathology, pharmacy, hospital episode and Cancer Registry records. We reviewed case notes on patients with subsequent muscle invasion (progression) or disease specific mortality. Patients underwent post-resection surveillance and treatment using standard regimens. National and regional disease specific mortality rates were calculated from appropriate data. RESULTS: A total of 699 patients met study inclusion criteria. Median followup was 61 months (IQR 24-105). Of the patients 17 (2.4%) died of bladder cancer, including 13 of 14 with progression to muscle invasion and 4 of 19 with grade progression to high grade, nonmuscle invasive disease. On Cox regression analyses low grade dysplasia in the initial resection specimen and tumor weight were associated with disease specific mortality (p <0.003). Disease specific mortality in these patients was 5 times the background rate in matched populations. Limitations of this study include its retrospective nature and the low frequency of adverse events. CONCLUSIONS:Patients with low risk bladder cancer rarely progress to muscle invasion but they are at higher risk for disease specific mortality than the general population. Current surveillance regimens appear ineffective for detecting progression in time to alter prognosis.
Authors: Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump Journal: Bladder Cancer Date: 2018-10-03
Authors: Rao S Mandalapu; Mesut Remzi; Theo M de Reijke; Vitaly Margulis; J Palou; A Kapoor; Ofer Yossepowitch; Jonathan Coleman; Olivier Traxer; J Kyle Anderson; James Catto; Jean de la Rosette; Timothy O'Brien; Anthony Zlotta; Surena F Matin Journal: World J Urol Date: 2016-05-27 Impact factor: 4.226
Authors: Johannes Breyer; Sanzhar Shalekenov; Atiqullah Aziz; Bastiaan W G van Rhijn; Johannes Bründl; Eva Lausenmeyer; Julius Schäfer; Stefan Denzinger; Christian Giedl; Maximilian Burger; Arndt Hartmann; Matthias Evert; Wolfgang Otto Journal: Bladder Cancer Date: 2017-07-27
Authors: Valeria Panebianco; Yoshifumi Narumi; Ersan Altun; Bernard H Bochner; Jason A Efstathiou; Shaista Hafeez; Robert Huddart; Steve Kennish; Seth Lerner; Rodolfo Montironi; Valdair F Muglia; Georg Salomon; Stephen Thomas; Hebert Alberto Vargas; J Alfred Witjes; Mitsuru Takeuchi; Jelle Barentsz; James W F Catto Journal: Eur Urol Date: 2018-05-10 Impact factor: 20.096
Authors: Samantha J Mason; Amy Downing; Penny Wright; Luke Hounsome; Sarah E Bottomley; Jessica Corner; Mike Richards; James W Catto; Adam W Glaser Journal: Br J Cancer Date: 2018-05-14 Impact factor: 7.640